Literature DB >> 7039438

Inhaled atropine sulfate: dose-response characteristics in adult patients with chronic airflow obstruction.

C C Pak, W A Kradjan, S Lakshminarayan, J J Marini.   

Abstract

Dose-response characteristics of inhaled atropine sulfate were examined in ten patients with chronic airflow obstruction using spirometric and plethysmographic measurements. Inhaled atropine in doses of 0.005, 0.01, 0.25, and 0.05 mg2kg of body weight and placebo were delivered by means of a precision metering device. All pulmonary function tests (FEV1, V50, and SGaw) improved progressively with increasing dose. There was a high degree of linear correlation between the peak response of each test and the logarithm of dose (r greater than or equal to 0.98). The highest dose studied (0.05 mg/kg) was found to have marginal benefit over 0.025 mg/kg, and had the highest incidence of adverse reactions. Duration of effect was dependent on dose. These results suggest that for adult patients with chronic airflow obstruction, 0.025 mg/kg delivered by a dosimeter approximates the optimally effective dose of inhaled atropine sulfate that can be given without unacceptable side effects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7039438     DOI: 10.1164/arrd.1982.125.3.331

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  4 in total

Review 1.  Perioperative management of the asthmatic patient.

Authors:  C A Hirshman
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

2.  Chest diseases: use of anticholinergic drugs for asthma.

Authors:  D P Tashkin
Journal:  West J Med       Date:  1986-03

3.  Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation.

Authors:  I G Brown; C S Chan; C A Kelly; A G Dent; P V Zimmerman
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

Review 4.  Acute respiratory failure and chronic obstructive lung disease.

Authors:  R L Rosen
Journal:  Med Clin North Am       Date:  1986-07       Impact factor: 5.456

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.